0.03
—
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kontafarma China Holdings
Its shares trade on HKEX under the ticker 1312.HK. It has been listed since 18 January 2012. In the fiscal year to 31 December 2025, it reported revenue of HK$914.7m and a net loss of HK$427.8m. At that date it held total assets of HK$1.07bn and shareholders' equity of HK$553.3m.
Kontafarma China Holdings Ltd. engages in the manufacture and sale of cement. The company employs 715 full-time employees The company went IPO on 2012-01-18. The firm operates its business through two business segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of prescription drugs, including chemical drugs and prescribed traditional Chinese medicines, and laboratory related products. The Fitness Business is segment is engaged in the operation of fitness centers, the provision of consultation services for fitness and health activities, as well as the operation of the franchise business for royalty fee income.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Jan 2012
- Employees
- 715
- Website
- tfkf.com.hk ↗
Leadership
Pay as last reported
- Mr. Feifei WangExecutive Chairman of the Board, President, since 2024
- Mr. Jie ZhangChief Operating Officer
- Ms. Linna QiaoVice President, Executive Director, since 2024
- Ms. Zixiu GuoFinancial Controller, Executive Director, since 2024
- Mr. Jiankun LiuExecutive Director, since 2024
- Ms. Lok Tung ChanCompany Secretary
- Mr. Yu HuangNon-Executive Director, since 2014HK$1.9m
- Dr. Ho Ming HoIndependent Non-Executive Director
- Dr. Lai Wah TangIndependent Non-Executive Director
- Mr. Xiaomin YaoIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kontafarma China Holdings Ltd employs 715 full-time employees in the Pharmaceuticals sector.
- The Pharmaceutical Business segment manufactures prescription drugs and traditional Chinese medicines.
- The Fitness Business segment generates royalty fee income from franchise operations.
Weaknesses
- The company operates in the Health Care sector with a focus on cement manufacturing.
- The Fitness Business segment provides consultation services for fitness and health activities.
- The company's business segments include cement and fitness, which are unrelated.
Opportunities
- The Pharmaceutical Business segment can expand prescription drug sales in China.
- The Fitness Business segment can grow franchise operations for royalty fee income.
- The company can leverage its 715 employees for sector growth in Health Care.
Threats
- The company's cement manufacturing business conflicts with its Health Care sector focus.
- The Fitness Business segment faces competition in the health and fitness market.
- The company's dual focus on cement and fitness may confuse investors.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.